Indoco Remedies Limited share price

Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc. In addition, it provides an…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: INDOCOISIN INE873D01024

16 Oct 2026, 3:30 PM IST₹245.65▲ 4.60 (1.91%)

Market Cap₹ 2,264 Cr.
Current Price₹ 245.65
High / Low₹ 293 / 162
Stock P/E767.7
Book Value₹ 112
Dividend Yield0.08 %
ROCE1.0 %
ROE-9.70 %
Face Value₹ 2.0

More figures (10)

EPS (TTM)₹ 0.32
Price / Book2.20
OPM0.9 %
Debt / Equity1.16
Sales growth (5Y)8.2 %
Profit growth (5Y)—
Promoter holding60.9 %
EV / EBITDA19.7
Beta0.62
All-time high₹ 530

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
INDOCO	-3.29%	-2.49%	+13.17%	+4.71%	-15.90%	-10.60%	-12.51%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Indoco Remedies Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹2,264 crore.
It trades at 767.7 times its last 12 months' earnings and 2.2 times book value.
Revenue grew 8.2% a year over the last 5 years.
Return on equity was -9.7% and return on capital employed 1.0% in the latest year.
Debt was 1.16 times shareholders' equity.
The share price is 16.2% below its 52-week high and down 15.9% over one year.
Promoters and insiders hold about 60.9%; institutions about 17.7%.

Pros

No standout strengths in the reported figures.

Cons

Return on equity has been low: -2.5% on average over the last 3 years.
Interest cover is thin: operating earnings are 0.3 times the interest cost.
Other income makes up 49% of profit before tax.
Trades at 767.7 times earnings, above its 3-year median of 31.5.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Indoco Remedies Limited

Employees: 6,000
Head office: Mumbai

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Indoco Remedies	245.65	767.7	2,264	0.08	65	—	468	6.76	1.0	-9.7	2.20	0.9	1.16	60.94	1,845	8.2
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 49 Co.	1,712.85	31.4	16,685	0.32	682	14.29	5,999	15.68	14.6	13.5	4.02	15.8	0.30	55.20	20,499	13.3

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	427	482	459	450	431	433	411	390	438	485	445	476	468
YOY Sales Growth %	4.48%	11.24%	15.09%	5.02%	1.17%	-10.19%	-10.64%	-13.22%	1.48%	12.02%	8.48%	21.89%	6.76%
	365	410	397	401	384	392	399	391	420	442	414	426	426
Material Cost %	30%	31%	31%	31%	33%	32%	28%	27%	31%	30%	27%	30%	34%
Employee Cost %	21%	19%	20%	20%	23%	21%	24%	27%	24%	21%	24%	23%	22%
Other Expenses %	34%	35%	36%	38%	34%	38%	46%	46%	41%	40%	42%	37%	36%
Operating Profit	61	71	63	49	48	40	12	-1	18	43	32	50	41
OPM %	14%	15%	14%	11%	11%	9%	3%	0%	4%	9%	7%	10%	9%
	0	4	2	3	1	2	1	2	2	1	1	-0	2
Exceptional items			-8	20			1			-1	-6	4	97
Interest	8	8	10	12	14	18	16	18	26	25	26	46	28
Depreciation	20	21	24	26	28	29	29	29	30	32	32	32	35
Profit before tax	34	46	23	33	7	-5	-31	-46	-37	-14	-31	-25	78
	29%	24%	31%	33%	74%								16%
Current tax	9	12	2	11	5	3	-5	-3		0	0	3	11
Deferred tax	1	-1	5	0	0	2	2	-1	-0	-4	-2	-4	2
	24	35	16	22	2	-10	-28	-41	-36	-9	-29	-24	65
Minority share	-0	0	-1	-1	-1	-0	-2	-1	-1	-1	0	-2	0
Profit to shareholders	24	35	16	23	3	-10	-26	-40	-36	-8	-30	-22	65
YOY Profit Growth %	-37.31%	-29.14%	-44.71%	-14.65%	-92.47%	-128.41%	-282.52%	-287.65%	-2,097.25%
EPS in Rs	2.62	3.82	1.69	2.39	0.20	-1.09	-3.08	-4.48	-3.94	-1.00	-3.20	-2.57	7.09
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	423	473	449	445	401	397	373	347	393	442	401	449	409
YOY Sales Growth %	3.67%	9.41%	12.65%	4.22%	-5.07%	-16.24%	-16.94%	-22.05%	-2.22%	11.50%	7.38%	29.34%	4.19%
	360	401	384	388	350	344	353	344	378	389	375	386	367
Material Cost %	30%	30%	30%	32%	33%	30%	28%	26%	31%	29%	28%	31%	34%
Employee Cost %	21%	19%	19%	19%	23%	22%	24%	29%	25%	22%	25%	22%	22%
Other Expenses %	34%	36%	36%	37%	32%	35%	42%	44%	40%	37%	41%	33%	33%
Operating Profit	63	72	65	57	52	53	20	3	15	53	26	63	42
OPM %	15%	15%	15%	13%	13%	13%	5%	1%	4%	12%	6%	14%	10%
	0	1	3	4	4	4	4	7	6	7	7	10	4
Exceptional items			-8	20			1			-1	-6	4	97
Interest	8	8	10	11	12	15	14	16	24	22	20	23	23
Depreciation	20	21	23	24	24	25	25	25	25	28	27	27	28
Profit before tax	36	44	27	47	20	17	-13	-31	-28	10	-20	28	93
	27%	25%	26%	19%	23%	26%				-54%		1%	12%
Current tax	9	12	2	10	5	3	-5	-3				3	11
Deferred tax	1	-1	5	-2	-0	1	2	-2	-0	-5	-0	-3	0
	26	33	20	38	15	13	-10	-26	-28	15	-20	27	82
YOY Profit Growth %	-32.57%	-33.24%	-28.20%	48.05%	-42.37%	-61.41%	-151.12%	-169.86%	-287.69%	17.67%
EPS in Rs	2.81	3.60	2.17	4.08	1.62	1.39	-1.11	-2.85	-3.04	1.63	-2.17	2.96	8.92
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	1,107	1,242	1,541	1,669	1,817	1,665	1,845	1,873
YOY Sales Growth %		12.19%	24.10%	8.30%	8.91%	-8.38%	10.84%
	983	1,017	1,213	1,383	1,573	1,566	1,704	1,708
Material Cost %	30%	29%	30%	31%	31%	30%	29%	30%
Employee Cost %	23%	22%	19%	19%	20%	24%	23%	22%
Other Expenses %	36%	31%	30%	32%	36%	40%	40%	39%
Operating Profit	123	224	327	286	244	99	142	165
OPM %	11%	18%	21%	17%	13%	6%	8%	9%
	2	3	2	2	10	5	3	4
Exceptional items					12	1	-3	94
Interest	26	22	14	25	38	66	122	124
Depreciation	71	73	79	71	92	114	126	131
Profit before tax	29	132	237	193	136	-74	-107	8
	16%	30%	35%	26%	29%			61%
Current tax	4	39	93	56	33	0	3
Deferred tax	1	0	-12	-5	6	3	-11
	24	93	155	142	97	-78	-99	3
Minority share					-1	-4	-4	-3
Profit to shareholders			155	142	98	-74	-95	6
YOY Profit Growth %		285.78%	66.36%	-8.11%	-31.80%	-180.35%
EPS in Rs	2.62	10.10	16.80	15.44	10.53	8.46	-10.70	0.32
Dividend Payout %				15%	21%

Compounded Sales Growth

5 Years:: 8%
3 Years:: 3%
TTM:: 12%

Stock Price CAGR

5 Years:: -13%
3 Years:: -11%
1 Year:: -16%

Return on Equity

4 Years:: 2%
Last Year:: -10%

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	1,042	968	1,106	1,240	1,540	1,667	1,791	1,518	1,686	1,701
YOY Sales Growth %		-7.09%	14.29%	12.14%	24.14%	8.25%	7.45%	-15.22%	11.06%
	907	891	983	1,017	1,213	1,382	1,533	1,390	1,529	1,516
Material Cost %	34%	33%	30%	29%	30%	31%	31%	29%	30%	31%
Employee Cost %	21%	24%	23%	22%	19%	19%	20%	24%	23%	23%
Other Expenses %	32%	35%	36%	31%	30%	32%	36%	38%	38%	36%
Operating Profit	135	77	123	224	327	285	258	128	157	185
OPM %	13%	8%	11%	18%	21%	17%	14%	8%	9%	11%
	5	6	2	3	2	2	9	18	30	29
Exceptional items							12	1	-3	94
Interest	24	21	26	22	14	25	37	57	89	88
Depreciation	68	72	71	73	79	71	88	98	107	110
Profit before tax	48	-9	29	131	236	192	153	-7	-11	110
	15%		16%	30%	35%	26%	24%			5%
Current tax	11		4	38	93	55	33		3
Deferred tax	-4	-6	1	0	-12	-5	4	1	-9
	41	-3	24	92	155	141	117	-9	-6	105
Profit to shareholders	41
YOY Profit Growth %		-106.89%		280.99%	67.25%	-8.52%	-17.49%	-107.48%
EPS in Rs	4.47	-0.31	2.63	10.03	16.77	15.34	12.66	-0.95	-0.61	11.34
Dividend Payout %						15%	18%

Compounded Sales Growth

5 Years:: 6%
3 Years:: 0%
TTM:: 13%

Stock Price CAGR

5 Years:: -13%
3 Years:: -11%
1 Year:: -16%

Return on Equity

4 Years:: 2%
Last Year:: -10%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	18	18	18	18
Reserves	1,010	1,091	1,004	921
	333	672	994	1,090
Long term borrowings	144	352	533	516
Short term borrowings	171	303	445	520
	297	363	414	564
Trade payables	123	154	208	309
Minority interest		1	-4	-7
Current liabilities	425	612	808	1,053
Total Liabilities	1,658	2,145	2,430	2,593
	706	979	1,213	1,082
Gross block	1,207	1,533	1,832	1,082
Accumulated depreciation	501	553	619
Goodwill & intangibles	124	188	192	201
CWIP	94	191	364	28
	858	974	853	1,483
Inventories	326	353	419	405
Trade receivables	351	406	352	489
Cash & equivalents	11	15	12	26
Current assets	814	955	1,001	1,193
Total Assets	1,658	2,145	2,430	2,593

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	179	155	91	226
Profit for the year	142	98	-74	-95
Working capital changes	-73	-88	-32	61
Direct taxes paid	-62	-29	-17	-6
	-208	-433	-260	-87
Fixed assets purchased	-207	-426	-258	-125
Fixed assets sold	1	2	4	44
Investments purchased	-3	-6
Investments sold			8
	23	122	169	-133
Proceeds from borrowings	95	251	201	53
Repayment of borrowings	-41	-49	-42	-68
Interest paid	-27	-36	-55	-89
Dividends paid	-21	-21	-14	-2
Net Cash Flow	-7	-155	-0	6
Free Cash Flow	-28	-271	-168	101

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	13.8%	9.2%	-6.9%	-9.7%
ROCE	—	17.6%	11.1%	-0.5%	1.0%
Operating margin	—	12.1%	8.0%	-0.9%	0.9%
Net margin	—	8.7%	5.5%	-4.5%	-5.3%
Debt / equity	—	0.32	0.61	0.97	1.16
Current ratio	—	1.92	1.56	1.24	1.13
Debtor days	—	78	83	78	100
Inventory days	—	221	221	307	273
Days payable	—	84	96	152	208
Cash conversion cycle	—	215	208	233	165
Working capital days	—	87	70	43	29

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 58.86%
FIIs 1.27%
DIIs 17.68%
Public 22.04%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	58.74%	58.74%	58.72%	58.75%	58.75%	58.80%	58.90%	58.90%	58.90%	58.90%	58.86%	58.86%
	1.59%	1.69%	1.91%	1.47%	1.70%	1.25%	1.24%	1.22%	1.25%	1.10%	0.94%	1.27%
Foreign portfolio investors (Cat. I)	1.44%	1.56%	1.75%	1.37%	1.47%	1.14%	1.07%	1.05%	1.04%	0.87%	0.67%	0.94%
Foreign portfolio investors (Cat. II)	0.15%	0.13%	0.17%	0.11%	0.23%	0.11%	0.17%	0.17%	0.21%	0.23%	0.27%	0.33%
	17.78%	19.56%	19.41%	18.67%	18.24%	18.90%	18.75%	18.96%	18.16%	18.15%	18.15%	17.68%
Mutual funds	16.61%	18.17%	17.91%	17.04%	16.74%	18.21%	18.52%	18.55%	17.58%	17.55%	17.54%	17.16%
Insurance companies	0.17%	0.33%	0.29%	0.13%	0.13%	0.13%
Alternative investment funds	1.01%	1.06%	1.21%	1.50%	1.38%	0.57%	0.23%	0.41%	0.58%	0.60%	0.61%	0.52%
	21.88%	20.00%	19.92%	21.07%	21.28%	21.03%	21.02%	20.83%	21.60%	21.77%	21.90%	22.04%
Retail (up to ₹2 lakh)	11.28%	9.70%	9.80%	10.77%	10.79%	10.40%	10.22%	10.18%	11.03%	11.11%	11.52%	11.66%
HNIs (above ₹2 lakh)	5.56%	5.53%	5.53%	5.52%	5.51%	5.66%	5.78%	5.60%	5.37%	5.36%	5.04%	5.02%
NRIs	0.61%	0.51%	0.56%	0.63%	0.66%	0.58%	0.61%	0.64%	0.65%	0.72%	0.72%	0.70%
Bodies corporate	2.62%	2.53%	2.33%	2.38%	2.49%	2.44%	2.47%	2.44%	2.49%	2.53%	2.57%	2.62%
IEPF	0.11%	0.11%	0.11%	0.11%	0.11%	0.18%	0.18%	0.18%	0.18%	0.16%	0.16%	0.16%
No. of Shareholders	36,588	32,600	33,201	34,511	34,416	34,676	34,497	33,129	33,319	32,659	32,276	32,457

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Indoco Remedies

Holder (above 1%)	Stake
Nippon India Small Cap FundMutual fund	4.80%
Quant Small Cap FundMutual fund	4.55%
DSP Healthcare FundMutual fund	4.34%
ICICI PRUDENTIAL PHARMA HEALTHCARE AND DIAGANOSTICS (P.H.D.) FUNDMutual fund · see the fund house	1.80%
HDFC Value FundMutual fund	1.66%

As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 17.16% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 10 Sep 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

Indoco Remedies (INDOCO.NS) Climbs 3.21% to ₹257.01, Nears Key Resistance Zone - Imbalance Zonehttps://www.siam.in/ · 21 Sep 2026

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Indoco Remedies Limited

What is the share price of Indoco Remedies Limited today?

Indoco Remedies Limited (INDOCO) last traded at ₹245.65 on NSE (16 Oct 2026, 3:30 PM IST). Prices may be delayed.

What is the market cap of Indoco Remedies Limited?

About ₹2,264 crore at the latest price.

What is the P/E ratio of Indoco Remedies Limited?

About 767.7 times its earnings over the last 12 months.

Is Indoco Remedies Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Indoco Remedies Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Indoco Remedies Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Indoco Remedies Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Indoco Remedies

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Indoco Remedies Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next